Novel HER2-targeted Bispecific Antibody for Biliary Tract Cancer
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA)...
Progress Against Cancer
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA)...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The...
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food...
The cell-based immunotherapy was approved for adults with relapsed or refractory acute lymphoblastic leukemia. The U.S. Food and Drug...
The therapeutic was approved for certain patients with Philadelphia chromosome-positive chronic myeloid leukemia. The U.S. Food and Drug Administration...
The FDA approved the claudin 18.2-targeted therapy Zolbetuximab-clzb for some gastric and gastroesophageal junction cancers. The U.S. Food and Drug...
The PI3K inhibitor is approved as part of combination therapy for certain patients whose breast cancer recurred on or...
The immunotherapy is now approved to treat certain lung cancers before and after surgery. The U.S. Food and Drug...
The accelerated approval of selpercatinib for certain patients with thyroid cancer was converted to a full approval. The U.S....
The EGFR inhibitor osimertinib is now available as a monotherapy for certain patients with locally advanced, unresectable non-small cell...